Mizuho raised the firm’s price target on UnitedHealth to $584 from $549 and keeps a Buy rating on the shares post the Q3 report. Although UnitedHealth did not provide detailed 2024 guidance, the company noted that consensus estimates are towards the high-end of the expected initial range, the analyst tells investors in a research note. The firm views the initial guidance as conservative and believes UnitedHealth will report earnings in-line with the company’s 13%-16% long-term guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on UNH:
- UnitedHealth price target raised to $605 from $555 at TD Cowen
- Wayfair upgraded, JD.com downgraded: Wall Street’s top analyst calls
- CVS biggest beneficiary of Medicare Advantage stars scores, says BofA
- UnitedHealth price target raised to $596 from $572 at RBC Capital
- UnitedHealth price target raised to $660 from $650 at BofA
